Hologic, Inc. (NASDAQ:HOLX) Holdings Decreased by Lindenwold Advisors INC

Lindenwold Advisors INC trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,835 shares of the medical equipment provider’s stock after selling 986 shares during the quarter. Hologic makes up approximately 1.1% of Lindenwold Advisors INC’s holdings, making the stock its 26th largest position. Lindenwold Advisors INC’s holdings in Hologic were worth $2,151,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in HOLX. Swedbank AB increased its holdings in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares during the last quarter. GSA Capital Partners LLP boosted its position in Hologic by 22.2% during the 3rd quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock valued at $469,000 after purchasing an additional 1,048 shares during the period. OneDigital Investment Advisors LLC boosted its position in Hologic by 5.4% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock valued at $576,000 after purchasing an additional 360 shares during the period. CIBC Asset Management Inc boosted its position in Hologic by 7.9% during the 3rd quarter. CIBC Asset Management Inc now owns 33,973 shares of the medical equipment provider’s stock valued at $2,767,000 after purchasing an additional 2,483 shares during the period. Finally, Empowered Funds LLC boosted its position in Hologic by 8.8% during the 3rd quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 291 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 0.3 %

Shares of Hologic stock opened at $61.98 on Wednesday. The firm has a market capitalization of $13.91 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock’s fifty day moving average is $66.72 and its 200-day moving average is $74.37.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HOLX. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Raymond James reissued an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.